Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151736224> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2151736224 endingPage "242" @default.
- W2151736224 startingPage "241" @default.
- W2151736224 abstract "Abstract Author Summary Background. Patients with recurrent cervical cancer in a previously irradiated area might benefit from cisplatin combined with hyperthermia. Lapatinib inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and HER2. Overexpression of EGFR and HER2 is frequently seen in patients with cervical cancer and is potentially involved in chemotherapy resistance. In addition, preclinical data suggest a synergistic effect of combining cisplatin and lapatinib. Consequently, this phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of lapatinib added to fixed doses of cisplatin and hyperthermia. Methods. Eight patients with previously irradiated recurrent cervical carcinoma were enrolled and scheduled for 6 weekly administrations of 70 mg/m2 cisplatin combined with locoregional hyperthermia. Hyperthermia consisted of the achievement of intraluminal temperatures of 40–43°C as homogeneously as possible over 60 minutes. Daily lapatinib was added on days 1–56, starting with a dose level of 1,000 mg. The MTD was defined as the highest dose at which ≤1 of 6 patients experienced dose-limiting toxicity (DLT). DLT was defined as grade 4 neutropenia lasting >7 days, febrile neutropenia grade ≥3, grade 4 thrombocytopenia, grade ≥2 renal toxicity, postponement of cisplatin and hyperthermia for ≥2 weeks, or grade ≥3 nonhematologic adverse events except for nausea or vomiting, diarrhea, or skin toxicity, for which the following DLT definitions were applied: grade ≥3 persistent nausea or vomiting or diarrhea despite optimal medical treatment or grade 4 skin toxicity. Safety, pharmacodynamics, and response were assessed. Results. The first two patients of both the 1,000- and 750-mg dose level experienced DLTs. Of the four patients treated at dose level −2 (500 mg), only one patient was able to complete the treatment as planned, two patients experienced a DLT, and one patient was not evaluable because of early progressive disease. In the evaluable patients, one patient with progressive disease, four patients with stable disease, and two patients with partial response were observed. One patient with a partial response had a resection of the local recurrence. Pathological analysis showed a complete pathological response. Enumeration of circulating endothelial cells measured at baseline and during therapy did not show consistent results. The same applied for the pharmacodynamic effects on Ki-67, p27Kip1, and EGFR in pretreatment and on-therapy skin biopsies. Conclusion. It is not feasible to combine lapatinib with fixed doses of cisplatin and hyperthermia in patients with recurrent cervical carcinoma in a previously irradiated area mainly because of increased cisplatin-related toxicity. The observed complete pathological response is intriguing and warrants further investigation of combinations consisting of HER2 blockade and cisplatin plus hyperthermia." @default.
- W2151736224 created "2016-06-24" @default.
- W2151736224 creator A5007237048 @default.
- W2151736224 creator A5013888438 @default.
- W2151736224 creator A5035333937 @default.
- W2151736224 creator A5047837719 @default.
- W2151736224 creator A5050851914 @default.
- W2151736224 creator A5071697710 @default.
- W2151736224 creator A5086664857 @default.
- W2151736224 date "2015-02-06" @default.
- W2151736224 modified "2023-10-18" @default.
- W2151736224 title "Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area" @default.
- W2151736224 doi "https://doi.org/10.1634/theoncologist.2014-0365" @default.
- W2151736224 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4350800" @default.
- W2151736224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25660155" @default.
- W2151736224 hasPublicationYear "2015" @default.
- W2151736224 type Work @default.
- W2151736224 sameAs 2151736224 @default.
- W2151736224 citedByCount "8" @default.
- W2151736224 countsByYear W21517362242015 @default.
- W2151736224 countsByYear W21517362242016 @default.
- W2151736224 countsByYear W21517362242017 @default.
- W2151736224 countsByYear W21517362242019 @default.
- W2151736224 countsByYear W21517362242020 @default.
- W2151736224 crossrefType "journal-article" @default.
- W2151736224 hasAuthorship W2151736224A5007237048 @default.
- W2151736224 hasAuthorship W2151736224A5013888438 @default.
- W2151736224 hasAuthorship W2151736224A5035333937 @default.
- W2151736224 hasAuthorship W2151736224A5047837719 @default.
- W2151736224 hasAuthorship W2151736224A5050851914 @default.
- W2151736224 hasAuthorship W2151736224A5071697710 @default.
- W2151736224 hasAuthorship W2151736224A5086664857 @default.
- W2151736224 hasBestOaLocation W21517362241 @default.
- W2151736224 hasConcept C121608353 @default.
- W2151736224 hasConcept C126322002 @default.
- W2151736224 hasConcept C126894567 @default.
- W2151736224 hasConcept C143998085 @default.
- W2151736224 hasConcept C197934379 @default.
- W2151736224 hasConcept C2776694085 @default.
- W2151736224 hasConcept C2777063308 @default.
- W2151736224 hasConcept C2777329042 @default.
- W2151736224 hasConcept C2778220009 @default.
- W2151736224 hasConcept C2778239845 @default.
- W2151736224 hasConcept C2779786085 @default.
- W2151736224 hasConcept C2779949491 @default.
- W2151736224 hasConcept C2780580376 @default.
- W2151736224 hasConcept C2780852908 @default.
- W2151736224 hasConcept C29730261 @default.
- W2151736224 hasConcept C530470458 @default.
- W2151736224 hasConcept C71924100 @default.
- W2151736224 hasConcept C90924648 @default.
- W2151736224 hasConceptScore W2151736224C121608353 @default.
- W2151736224 hasConceptScore W2151736224C126322002 @default.
- W2151736224 hasConceptScore W2151736224C126894567 @default.
- W2151736224 hasConceptScore W2151736224C143998085 @default.
- W2151736224 hasConceptScore W2151736224C197934379 @default.
- W2151736224 hasConceptScore W2151736224C2776694085 @default.
- W2151736224 hasConceptScore W2151736224C2777063308 @default.
- W2151736224 hasConceptScore W2151736224C2777329042 @default.
- W2151736224 hasConceptScore W2151736224C2778220009 @default.
- W2151736224 hasConceptScore W2151736224C2778239845 @default.
- W2151736224 hasConceptScore W2151736224C2779786085 @default.
- W2151736224 hasConceptScore W2151736224C2779949491 @default.
- W2151736224 hasConceptScore W2151736224C2780580376 @default.
- W2151736224 hasConceptScore W2151736224C2780852908 @default.
- W2151736224 hasConceptScore W2151736224C29730261 @default.
- W2151736224 hasConceptScore W2151736224C530470458 @default.
- W2151736224 hasConceptScore W2151736224C71924100 @default.
- W2151736224 hasConceptScore W2151736224C90924648 @default.
- W2151736224 hasIssue "3" @default.
- W2151736224 hasLocation W21517362241 @default.
- W2151736224 hasLocation W21517362242 @default.
- W2151736224 hasLocation W21517362243 @default.
- W2151736224 hasLocation W21517362244 @default.
- W2151736224 hasOpenAccess W2151736224 @default.
- W2151736224 hasPrimaryLocation W21517362241 @default.
- W2151736224 hasRelatedWork W2348688227 @default.
- W2151736224 hasRelatedWork W2350418051 @default.
- W2151736224 hasRelatedWork W2355640969 @default.
- W2151736224 hasRelatedWork W2379383495 @default.
- W2151736224 hasRelatedWork W2386923354 @default.
- W2151736224 hasRelatedWork W2412619742 @default.
- W2151736224 hasRelatedWork W2418644999 @default.
- W2151736224 hasRelatedWork W2897258609 @default.
- W2151736224 hasRelatedWork W3149628602 @default.
- W2151736224 hasRelatedWork W57680343 @default.
- W2151736224 hasVolume "20" @default.
- W2151736224 isParatext "false" @default.
- W2151736224 isRetracted "false" @default.
- W2151736224 magId "2151736224" @default.
- W2151736224 workType "article" @default.